Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Corient Private Wealth LLC

Corient Private Wealth LLC grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 111.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 45,799 shares of the biotechnology company’s stock after purchasing an additional 24,108 shares during the period. Corient Private Wealth LLC’s holdings in Exelixis were worth $1,523,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Natixis Advisors LLC boosted its holdings in shares of Exelixis by 26.2% in the third quarter. Natixis Advisors LLC now owns 29,113 shares of the biotechnology company’s stock worth $755,000 after buying an additional 6,051 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Exelixis during the 3rd quarter worth approximately $1,972,000. Advisors Asset Management Inc. grew its position in Exelixis by 3.2% during the 3rd quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company’s stock worth $515,000 after purchasing an additional 609 shares in the last quarter. Cerity Partners LLC lifted its holdings in shares of Exelixis by 129.1% in the third quarter. Cerity Partners LLC now owns 27,994 shares of the biotechnology company’s stock valued at $726,000 after purchasing an additional 15,777 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Exelixis in the third quarter worth $591,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insiders Place Their Bets

In related news, Director Mary C. Beckerle sold 12,210 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the transaction, the director now owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Christopher J. Senner sold 29,314 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the completion of the sale, the chief financial officer now directly owns 779,607 shares of the company’s stock, valued at approximately $28,174,996.98. This trade represents a 3.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock valued at $5,177,234 in the last three months. Company insiders own 2.85% of the company’s stock.

Exelixis Trading Down 0.0 %

NASDAQ EXEL opened at $37.71 on Wednesday. The company has a market cap of $10.55 billion, a P/E ratio of 21.31, a P/E/G ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 1 year low of $20.14 and a 1 year high of $40.02. The company has a fifty day simple moving average of $35.70 and a 200 day simple moving average of $33.09.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Equities research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on EXEL. Barclays upped their price target on Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Guggenheim reissued a “buy” rating and issued a $42.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 19th. Stephens reissued an “equal weight” rating and set a $29.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. Finally, Wells Fargo & Company downgraded shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price target on the stock. in a research note on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Exelixis has a consensus rating of “Moderate Buy” and an average price target of $37.59.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.